Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine (GlobeNewswire) - Oct 4, 2022 - "Plus Therapeutics, Inc...announced it will present data from two ongoing clinical trials evaluating the Company's lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma and leptomeningeal metastases at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), being held October 15-19, 2022 in Barcelona, Spain."
P1 data • P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|